WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 562298
CAS#: 404828-08-6
Description: GSK3i XIII is an ATP-binding site inhibitor of GSK-3.
MedKoo Cat#: 562298
Name: GSK3i XIII
CAS#: 404828-08-6
Chemical Formula: C18H15N5
Exact Mass: 301.1327
Molecular Weight: 301.353
Elemental Analysis: C, 71.74; H, 5.02; N, 23.24
Synonym: GSK3i XIII; GSK3i-XIII; GSK3iXIII; GSK3 inhibitor XIII;
IUPAC/Chemical Name: (5-Methyl-1H-pyrazol-3-yl)-(2-phenylquinazolin-4-yl)amine
InChi Key: JYCUVOXSZBECAY-UHFFFAOYSA-N
InChi Code: InChI=1S/C18H15N5/c1-12-11-16(23-22-12)20-18-14-9-5-6-10-15(14)19-17(21-18)13-7-3-2-4-8-13/h2-11H,1H3,(H2,19,20,21,22,23)
SMILES Code: CC1=CC(NC2=C3C=CC=CC3=NC(C4=CC=CC=C4)=N2)=NN1
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
| Biological target: | GSK-3 Inhibitor XIII is a potent and ATP-competitive GSK-3 inhibitor with a Ki of 24 nM. |
| In vitro activity: | In cells pretreated with GSK3 inhibitor XIII (30μM) the Nav1.2-mediated peak current density was significantly higher (−169.7 ± 29.8 pA/pF, n=11, p<0.005) compared to control (−68.37 ± 7 pA/pF, n=8; Fig. 1A–C). Reference: Biochim Biophys Acta. 2015 Apr;1850(4):832-44. https://pubmed.ncbi.nlm.nih.gov/25615535/ |
| In vivo activity: | Treatment of gsk3WT mouse DCs with SB216763 (1 µM, 4–24 h) or GSK-XIII (10 µM, 4–24 h) did not significantly modify the protein abundance of Orai1, STIM1 and STIM2. Reference: PLoS One. 2014 Feb 11;9(2):e88637. https://pubmed.ncbi.nlm.nih.gov/24523925/ |
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| DMF | 0.25 | 0.83 | |
| DMSO | 0.15 | 0.5 |
The following data is based on the product molecular weight 301.353 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | 1. James TF, Nenov MN, Wildburger NC, Lichti CF, Luisi J, Vergara F, Panova-Electronova NI, Nilsson CL, Rudra JS, Green TA, Labate D, Laezza F. The Nav1.2 channel is regulated by GSK3. Biochim Biophys Acta. 2015 Apr;1850(4):832-44. doi: 10.1016/j.bbagen.2015.01.011. Epub 2015 Jan 20. PMID: 25615535; PMCID: PMC4336163. 2. Moraes EC, Meirelles GV, Honorato RV, de Souza Tde A, de Souza EE, Murakami MT, de Oliveira PS, Kobarg J. Kinase inhibitor profile for human nek1, nek6, and nek7 and analysis of the structural basis for inhibitor specificity. Molecules. 2015 Jan 13;20(1):1176-91. doi: 10.3390/molecules20011176. PMID: 25591119; PMCID: PMC6272266. 3. Schmid E, Yan J, Nurbaeva MK, Russo A, Yang W, Faggio C, Shumilina E, Lang F. Decreased store operated Ca2+ entry in dendritic cells isolated from mice expressing PKB/SGK-resistant GSK3. PLoS One. 2014 Feb 11;9(2):e88637. doi: 10.1371/journal.pone.0088637. PMID: 24523925; PMCID: PMC3921210. |
| In vitro protocol: | 1. James TF, Nenov MN, Wildburger NC, Lichti CF, Luisi J, Vergara F, Panova-Electronova NI, Nilsson CL, Rudra JS, Green TA, Labate D, Laezza F. The Nav1.2 channel is regulated by GSK3. Biochim Biophys Acta. 2015 Apr;1850(4):832-44. doi: 10.1016/j.bbagen.2015.01.011. Epub 2015 Jan 20. PMID: 25615535; PMCID: PMC4336163. 2. Moraes EC, Meirelles GV, Honorato RV, de Souza Tde A, de Souza EE, Murakami MT, de Oliveira PS, Kobarg J. Kinase inhibitor profile for human nek1, nek6, and nek7 and analysis of the structural basis for inhibitor specificity. Molecules. 2015 Jan 13;20(1):1176-91. doi: 10.3390/molecules20011176. PMID: 25591119; PMCID: PMC6272266. |
| In vivo protocol: | 1. Schmid E, Yan J, Nurbaeva MK, Russo A, Yang W, Faggio C, Shumilina E, Lang F. Decreased store operated Ca2+ entry in dendritic cells isolated from mice expressing PKB/SGK-resistant GSK3. PLoS One. 2014 Feb 11;9(2):e88637. doi: 10.1371/journal.pone.0088637. PMID: 24523925; PMCID: PMC3921210. |
1: James TF, Nenov MN, Wildburger NC, Lichti CF, Luisi J, Vergara F, Panova-Electronova NI, Nilsson CL, Rudra JS, Green TA, Labate D, Laezza F. The Nav1.2 channel is regulated by GSK3. Biochim Biophys Acta. 2015 Apr;1850(4):832-44. doi: 10.1016/j.bbagen.2015.01.011. Epub 2015 Jan 20. PubMed PMID: 25615535; PubMed Central PMCID: PMC4336163.
2: Schütz SV, Cronauer MV, Rinnab L. Inhibition of glycogen synthase kinase-3beta promotes nuclear export of the androgen receptor through a CRM1-dependent mechanism in prostate cancer cell lines. J Cell Biochem. 2010 Apr 15;109(6):1192-200. doi: 10.1002/jcb.22500. PubMed PMID: 20127713.
3: Rinnab L, Schütz SV, Diesch J, Schmid E, Küfer R, Hautmann RE, Spindler KD, Cronauer MV. Inhibition of glycogen synthase kinase-3 in androgen-responsive prostate cancer cell lines: are GSK inhibitors therapeutically useful? Neoplasia. 2008 Jun;10(6):624-34. PubMed PMID: 18516299; PubMed Central PMCID: PMC2386547.
